title: Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
abstract: The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: -22.6 (P < .001), -22.3 (P < .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations.
authors.affiliation: Italian Group for Adult Hematologic Diseases, Data Center and Health Outcomes Research Unit, Rome, Italy. f.efficace@gimema.it
authors.forename: Fabio
authors.initials: F
authors.lastname: Efficace
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
authors.forename: Gianantonio
authors.initials: G
authors.lastname: Rosti
authors.forename: Francesco
authors.initials: F
authors.lastname: Cottone
authors.forename: Giorgio Lambertenghi
authors.initials: GL
authors.lastname: Deliliers
authors.forename: Claudia
authors.initials: C
authors.lastname: Baratè
authors.forename: Antonella Russo
authors.initials: AR
authors.lastname: Rossi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Fioritoni
authors.forename: Luigia
authors.initials: L
authors.lastname: Luciano
authors.forename: Diamante
authors.initials: D
authors.lastname: Turri
authors.forename: Bruno
authors.initials: B
authors.lastname: Martino
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Raimondo
authors.forename: Melissa
authors.initials: M
authors.lastname: Dabusti
authors.forename: Micaela
authors.initials: M
authors.lastname: Bergamaschi
authors.forename: Pietro
authors.initials: P
authors.lastname: Leoni
authors.forename: Maria Pina
authors.initials: MP
authors.lastname: Simula
authors.forename: Luciano
authors.initials: L
authors.lastname: Levato
authors.forename: Stefano
authors.initials: S
authors.lastname: Ulisciani
authors.forename: Dino
authors.initials: D
authors.lastname: Veneri
authors.forename: Simona
authors.initials: S
authors.lastname: Sica
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
authors.forename: Marco
authors.initials: M
authors.lastname: Vignetti
authors.forename: Franco
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides; D003430:Cross-Sectional Studies; D005260:Female; D006304:Health Status; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000453:epidemiology* / Q000523:psychology; D060046:Maintenance Chemotherapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011153:Population; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D013997:Time Factors; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate